This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-03. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
But creating a type of airplane named AIRPLANE doesn't make you Wilbur Wright." Thomas Haigh, a historian of information technology at the University of Wisconsin–Milwaukee, wrote that "Ayyadurai is, to the best of my knowledge, the only person to have claimed for him or herself the title 'inventor of email'." Haigh argued that while EMAIL was impressive for a teenager's work, it contained no features that were not present on previous electronic mail systems and had no obvious influence on later systems. "The most striking thing about Ayyadurai's claim to have invented electronic mail is how late it comes. Somehow it took him thirty years to alert the world to [his] greatest achievement". Haigh wrote that by 1980, "electronic mail had been in use at MIT for 15 years, Xerox had built a modern, mouse-driven graphical email system for office communication, Compuserve was selling email access to the public, and email had for many years been the most popular application on what was soon to become the Internet." Haigh wrote that Ayyadurai had created "infographic" outlines for his view of history and published the assembled documents under various domain names that he had registered to support his claim. Through his infographics, wrote Haigh, Ayyadurai presented his claims that he "designed and deployed the first version of electronic [mail] system" in 1980, although electronic mail as an executable program was used under the name "Electronic Mail System" before.
=== Pharmacokinetics === Following single or multiple intravenous infusions, the majority of drug elimination occurs within 24 hours of intravenous administration. The elimination half-life of golodirsen, in parity with eteplirsen was 3 to 6 hours.
By 25 September, an army of around 40,000 Iraqi, Syrian, and Houthi militants were concentrated around the Golan Heights, which the Institute for the Study of War argued was to defend against an Israeli invasion of Lebanon. The number of displaced Lebanese people reached an estimated 500,000. On 26 September, an Israeli strike on a three-story building in Younine killed at least 19 Syrians and a Lebanese person, mostly women or children, and injured eight others. On 27 September, Israel struck Hezbollah's central headquarters in Beirut, targeting Hezbollah leader Hassan Nasrallah. Al-Manar reported that four buildings collapsed in the attack. At least five other people died, including Ali Karaki, Hezbollah's commander of the southern front since 1982, and at least 100 were injured. On 28 September, the Lebanese National News Agency reported that IDF strikes struck civil defense centres and a medical clinic in Taybeh and Deir Siriane killing 11 medical staff and injuring 10 others. On 29 September, an Israeli air strike on a home in Dahr-al-Ain killed at least 11 people. The Lebanese National News Agency reported that at least 17 members of a family were killed and several others were trapped under rubble in an Israeli air strike in Zboud. An Israeli strike in Ain El Delb killed 45 people and injured at least 75 others. An Israeli strike in Bekaa killed 12 people and injured 20 others. On 30 September, Israel informed the United States that it intended to carry out a ground maneuver in Lebanon aimed at clearing Hezbollah's infrastructure along the border.
creating non-viral transfection agents, developing preparations for biotechnological production and gene therapy; creating new programmable materials based on hybrid nanoparticles for medicine and biochemistry; developing direct synthesis methods, studying structure and properties of new sulphur derivatives of five-membered oxygen- and nitrogen-containing heterocycles; searching for chemo-, region- and stereo-selective thiating and aminating reactions with the view to create new antimicrobial agents based on studied heterocycles; developing new principles of pathogenic microflora control in collaboration with biologists. New organic synthesis methods are developed here, as well.
Sources: en.wikipedia.org
==== Cell voltage ==== The average voltage of LCO (lithium cobalt oxide) chemistry is 3.6 V if made with hard carbon anode and 3.7 V if made with graphite anode. Comparatively, the latter has a flatter discharge voltage curve.
==== Hard disk ==== The use of hard disk storage has increased over time as it has become progressively cheaper. Hard disks are usually easy to use, widely available, and can be accessed quickly. However, hard disk backups are close-tolerance mechanical devices and may be more easily damaged than tapes, especially while being transported. In the mid-2000s, several drive manufacturers began to produce portable drives employing ramp loading and accelerometer technology (sometimes termed a "shock sensor"), and by 2010 the industry average in drop tests for drives with that technology showed drives remaining intact and working after a 36-inch non-operating drop onto industrial carpeting. Some manufacturers also offer 'ruggedized' portable hard drives, which include a shock-absorbing case around the hard disk, and claim a range of higher drop specifications. Over a period of years the stability of hard disk backups is shorter than that of tape backups. External hard disks can be connected via local interfaces like SCSI, USB, FireWire, or eSATA, or via longer-distance technologies like Ethernet, iSCSI, or Fibre Channel. Some disk-based backup systems, via Virtual Tape Libraries or otherwise, support data deduplication, which can reduce the amount of disk storage capacity consumed by daily and weekly backup data.
In 1929, the cyclic nature of benzene was finally confirmed by the crystallographer Kathleen Lonsdale using X-ray diffraction methods. Using large crystals of hexamethylbenzene, a benzene derivative with the same core of six carbon atoms, Lonsdale obtained diffraction patterns. Through calculating more than thirty parameters, Lonsdale demonstrated that the benzene ring could not be anything but a flat hexagon, and provided accurate distances for all carbon-carbon bonds in the molecule.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.